Company / R&D per Share
Arcutis Biotherapeutics, Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.65
FY2025
5-year range
$0.65 / $3.32
FY2021-FY2025
Trend
-17.2%
vs FY2024
Sector context
#166 of 208
Health Care
What the data says
Arcutis Biotherapeutics, Inc.'s r&d per share of $0.65 is lower than 80% of companies in the Health Care sector (FY2025). R&D per Share has declined for 3 consecutive years, from $3.32 in FY2022 to $0.65 in FY2025.
Based on SEC 10-K filings.
0.65 in FY2025 with a 5-year CAGR of -27.4%.
Declined from $1.60 to $0.65 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -41.8%
- 5-Year CAGR
- -27.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 208This company $0.65 Sector average $12.19
▼
-94.6% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 17.2% year-over-year.
- Ranks #166 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.65 | -17.2% |
| FY2024 | $0.79 | -50.5% |
| FY2023 | $1.60 | -51.9% |
| FY2022 | $3.32 | +12.5% |
| FY2021 | $2.95 | -8.9% |
| FY2020 | $3.23 | -83.7% |
| FY2019 | $19.81 | +36.9% |
| FY2018 | $14.47 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026